SARS-CoV-2 spike protein mutations: Difference between revisions
Eric Martz (talk | contribs) No edit summary |
Eric Martz (talk | contribs) No edit summary |
||
| Line 85: | Line 85: | ||
*December 30, 2020: Added study showing no increased hospitalization or death for B.1.1.7 compared to wild type SARS-CoV-2<ref name="phe1" />. | *December 30, 2020: Added study showing no increased hospitalization or death for B.1.1.7 compared to wild type SARS-CoV-2<ref name="phe1" />. | ||
*January 4, 2021: Added evidence that the mutant lineages are more contagious<ref name="leonhardt1" />. | *January 4, 2021: Added evidence that the mutant lineages are more contagious<ref name="leonhardt1" />. | ||
*January 5, 2021: Added a [[#Vaccine Effectiveness Under Investigation|new subsection]] about concerns over vaccine effectiveness, with two new references<ref name="smc1" /><ref name="kozlov1" />. | *January 5, 2021: Added a [[#Vaccine Effectiveness Under Investigation|new subsection]] about concerns over vaccine effectiveness, with two new references<ref name="smc1" /><ref name="kozlov1">[https://www.the-scientist.com/news-opinion/south-african-sars-cov-2-variant-alarms-scientists-68317 South African SARS-CoV-2 Variant Alarms Scientists], Max Kozlov, The Scientist, January 5, 2021.</ref>. | ||
*January 6, 2021: Cited analysis of events that have inadvertently favored mutations to evade vaccine effectiveness<ref name="bieniasz" />. | *January 6, 2021: Cited analysis of events that have inadvertently favored mutations to evade vaccine effectiveness<ref name="bieniasz" />. | ||
*January 7, 2021: Added a preprint showing that some of the mutations in B.1.1.7 and 501.V2 increase binding affinity between the spike protein and its receptor ACE2<ref name="zahradnik" />. | *January 7, 2021: Added a preprint showing that some of the mutations in B.1.1.7 and 501.V2 increase binding affinity between the spike protein and its receptor ACE2<ref name="zahradnik" />. | ||